Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women with Hiv: Laboratory and Clinical Outcomes in an Observational National Study
Articolo
Data di Pubblicazione:
2018
Citazione:
Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women with Hiv: Laboratory and Clinical Outcomes in an Observational National Study / Floridia, Marco; Pinnetti, Carmela; Ravizza, Marina; Masuelli, Giulia; Personeni, Carlo; Sansone, Matilde; Antoni, Anna Degli; Guaraldi, Giovanni; Spinillo, Arsenio; Tassis, Beatrice; Dalzero, Serena; Liuzzi, Giuseppina; Tamburrini, Enrica. - In: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. - ISSN 1525-4135. - 78:1(2018), pp. 99-104. [10.1097/QAI.0000000000001640]
Abstract:
Abacavir-lamivudine (ABC/3TC) and tenofovir-emtricitabine (TDF/FTC) represent in the guidelines of several countries, including Italy and United States, the preferred nucleoside/nucleotide backbones of antiretroviral regimens. We assessed their profile in pregnancy using data from a national observational study.
Tipologia CRIS:
Articolo su rivista
Keywords:
Abacavir; Anemia; Cholesterol; Emtricitabine; HIV-RNA; Lamivudine; Low birthweight; Pregnancy; Preterm delivery; Tenofovir;
Elenco autori:
Floridia, Marco; Pinnetti, Carmela; Ravizza, Marina; Masuelli, Giulia; Personeni, Carlo; Sansone, Matilde; Antoni, Anna Degli; Guaraldi, Giovanni; Spinillo, Arsenio; Tassis, Beatrice; Dalzero, Serena; Liuzzi, Giuseppina; Tamburrini, Enrica
Link alla scheda completa:
Pubblicato in: